Michael Thorpy News Today

Michael Thorpy, MD, professor of neurology, Albert Einstein College of Medicine, discusses promising pharmacological treatments for patients with idiopathic hypersomnia.

Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced five presentations, including two featured oral plenary presentations, on...

Axsome will unveil data demonstrating solriamfetol's ability to enhance cognitive functioning in patients with OSA and narcolepsy.

Here are some updates from the world of psychiatry throughout the month of March.

The treatment significantly reduced the frequency of cataplexy attacks in patients with narcolepsy compared with placebo.

AXS-12 statistically significantly reduced cataplexy attacks compared to placebo AXS-12 achieved statistically significant remission of cataplexy compared to placebo AXS-12 statistically...

The SYMPHONY trial found reboxetine can significantly reduce cataplexy, excessive daytime sleepiness, cognitive impairment, depression, and anxiety for patients with narcolepsy.

Axsome Therapeutics announced topline trial results, which show AXS-12 significantly improves key narcolepsy symptoms.

ZURICH, SWITZERLAND / ACCESSWIRE / November 27, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW)) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery

In part 3 of this 4-part series, Michael Thorpy, MD, talks about advances in sodium oxybate medication formulations and how different formulations can help patients depending on their needs.